Top Page
PYC Therapeutics Limited
(Sydney:PYC)
PYC Therapeutics Limited (PYC) vs. iShares MSCI Australia ETF (EWA)
PYC Therapeutics Limited Business Overview & Revenue Model
PYC Therapeutics Limited Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.06M | 15.81M | 16.04M | 3.07M | 2.40M |
| Gross Profit | 22.06M | 14.92M | 15.20M | 2.45M | 1.85M |
| EBITDA | -38.12M | -38.25M | -29.39M | -21.04M | -8.89M |
| Net Income | -37.73M | -22.79M | -13.86M | -17.77M | -6.82M |
Balance Sheet | |||||
| Total Assets | 91.24M | 37.17M | 45.35M | 57.94M | 31.55M |
| Cash, Cash Equivalents and Short-Term Investments | 66.87M | 15.57M | 29.11M | 51.50M | 25.43M |
| Total Debt | 1.11M | 315.49K | 943.77K | 730.35K | 798.14K |
| Total Liabilities | 10.18M | 8.72M | 5.15M | 4.02M | 1.35M |
| Stockholders Equity | 80.50M | 27.75M | 39.35M | 53.04M | 28.45M |
Cash Flow | |||||
| Free Cash Flow | -38.90M | -24.91M | -22.17M | -12.38M | -5.85M |
| Operating Cash Flow | -38.59M | -24.42M | -21.78M | -11.79M | -5.75M |
| Investing Cash Flow | -307.04K | -477.12K | 32.68M | -15.52M | -13.77M |
| Financing Cash Flow | 90.19M | 11.44M | -182.36K | 38.56M | 25.11M |
PYC Therapeutics Limited Technical Analysis
PYC Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $544.34M | 14.39 | 19.93% | 0.46% | 12.74% | 27.56% | |
54 Neutral | AU$793.23M | ― | -112.97% | ― | ― | -84.82% | |
53 Neutral | AU$1.10B | ― | -53.99% | ― | ― | -40.19% | |
53 Neutral | AU$294.17M | ― | -56.99% | ― | 10.76% | -195.89% | |
50 Neutral | $365.10M | ― | -31.16% | ― | ― | 14.47% | |
50 Neutral | AU$2.51B | 3.43 | -57.47% | 2.67% | 36.73% | 13.67% | |
30 Underperform | $738.77M | ― | ― | -24.46% | -7.90% |
PYC Therapeutics Limited Corporate Events
PYC Therapeutics has announced the progression of its clinical trials for PYC-003, a drug candidate targeting Polycystic Kidney Disease (PKD). Following approval from the Safety Review Committee, the company will advance to Part B of the Single Ascending Dose study and escalate dosing in Part A. This milestone allows PYC to commence patient dosing and aligns with their timeline to initiate repeat dose studies by Q4 2025, marking significant progress in their efforts to address PKD.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics announced progress in its Phelan-McDermid Syndrome (PMS) program, presenting data at the PMS Global Congress in Barcelona. The data shows that their drug candidate, PYC-002, restores missing gene expression and rescues functional deficits in neurons, addressing the underlying cause of PMS. This advancement is significant as there are currently no approved treatments for PMS, and the program is expected to enter clinical trials in about 12 months, marking the company’s fourth first-in-class drug candidate with disease-modifying potential.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has received FDA alignment on the design of its registrational trial for VP-001, a drug candidate aimed at treating Retinitis Pigmentosa type 11 (RP11), a blinding eye disease. The FDA’s acceptance of PYC’s trial design, including the use of a sham control arm and specific inclusion criteria, marks a significant step towards a New Drug Application. This progress could enhance PYC’s positioning in the biotechnology industry by advancing its clinical pipeline and potentially offering a new treatment option for RP11 patients.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has received approval from the Safety Review Committee to escalate the dose of its investigational drug candidate, PYC-001, in its clinical trial for Autosomal Dominant Optic Atrophy (ADOA). This approval allows the company to move from cohort 2 to cohort 3, increasing the dose from 10 to 30 micrograms per eye. The progression of this trial is a significant step towards establishing the safety and efficacy of PYC-001, with plans for further studies and a potential Phase 2/3 trial to support a New Drug Application.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited recently held a Q2 investor webinar to update stakeholders on its business activities. The presentation emphasized the company’s ongoing commitment to advancing its scientific endeavors, though it cautioned that the information provided should be considered in conjunction with past and future announcements. The company highlighted the inherent risks and uncertainties in its forward-looking statements, urging stakeholders to exercise caution when interpreting the information.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has received approval to escalate dosing in its clinical trial for PYC-003, a drug candidate for Polycystic Kidney Disease (PKD). The Safety Review Committee has approved the increase in dosage for the second cohort of healthy volunteers, with plans to initiate dosing in PKD patients upon successful review of safety data. This progression marks a significant step in PYC’s clinical trial process, potentially leading to a Phase 2/3 trial aimed at supporting a New Drug Application for PYC-003.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited announced the cessation of certain securities due to unmet conditions, affecting options expiring in 2026, 2027, and 2028. This announcement may impact the company’s capital structure and investor relations, as it reflects on the company’s strategic decisions regarding its financial instruments.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has announced an investor webinar scheduled for May 30, 2025, to update shareholders on its progress in Q2 2025. The company is advancing several drug development programs, including treatments for Retinitis Pigmentosa type 11, Autosomal Dominant Optic Atrophy, Autosomal Dominant Polycystic Kidney Disease, and Phelan McDermid Syndrome. These programs are at various stages of clinical trials, with significant milestones anticipated in 2025 and 2026, potentially impacting the company’s market position and stakeholder interests.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited announced the results of its Phase 1/2 clinical trials for Retinitis Pigmentosa type 11, a blinding eye disease, at the Foundation Fighting Blindness Retinal Therapeutics Innovation Summit. This development marks a significant step in PYC’s efforts to provide treatment options for genetic diseases with no current therapies, potentially enhancing its position in the RNA therapeutics market.
PYC Therapeutics Limited has announced a change in the interests of a substantial holder, Australian Land Pty Ltd, and other entities associated with Mr. Alan Tribe. The change, effective from April 23, 2025, reflects a shift in voting power due to a series of entitlement offers and share consolidations. This adjustment in shareholding structure may impact the company’s governance dynamics and influence future strategic decisions.
PYC Therapeutics announced promising results from Phase 1/2 clinical trials of its drug candidate VP-001, aimed at treating Retinitis Pigmentosa type 11. The data, to be presented at upcoming international conferences, shows significant improvements in vision and quality of life for patients, with the drug being safe and well-tolerated. This positions PYC’s platform technology as a valuable tool in addressing blinding eye diseases, with plans to discuss a New Drug Application pathway with the FDA in June 2025.
PYC Therapeutics has made significant progress in Q1 2025 towards becoming a commercial-stage drug developer, extending its cash runway to over $200 million through a $146 million Entitlement Offer. This funding supports the advancement of its drug candidates, including human trials for polycystic kidney disease and ongoing studies in Retinitis Pigmentosa, positioning the company for improved market conditions and stakeholder confidence.
PYC Therapeutics Limited has announced the application for the quotation of 32,313,759 ordinary fully paid securities on the Australian Securities Exchange (ASX), with the issue date set for April 24, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning and providing opportunities for stakeholders.